Therapeutic Outcomes of Transplanting Autologous Granulocyte Colony-stimulating Factor-mobilised Peripheral Mononuclear Cells in Diabetic Patients with Critical Limb Ischaemia

Abstract

The efficacy and safety of transplanting autologous mesenchymal stem cells (MSCs), from granulocyte-colony-stimulating factor (G-CSF)-mobilised peripheral blood, was investigated in diabetic patients with critical limb ischaemia (CLI). After 3 months, the transplanted group of patients (n=7) showed a significant improvement in ischaemia manifestations, including pain and neurological signs, wound healing and the rate of lower-limb amputation, compared to the control group of patients (n=14). Pain was significantly reduced in the transplanted group compared to controls (P=0.014). The ankle-brachial index (ABI) and the pulse strength within ischaemic tissues of the transplanted group were significantly improved (P=0.035 and P=0.01, respectively). Importantly, 50% of the control group (7/14 patients) faced major amputation of a limb at the study's conclusion, compared to none of 7 patients in the transplanted group (P=0.047). The safety of transplantation was confirmed by observing no adverse reactions among the transplanted group, including infection and immunological rejection. Hence, this study provides further evidence that transplantation of autologous peripheral blood MSCs, mobilised by G-CSF, induces angiogenesis and improves the wound healing process in diabetic patients with CLI.

Efficiency of stem cell based therapy in the treatment of diabetic foot ulcer: a meta-analysis

“…Following careful screening of titles and abstracts, 399 articles were excluded leaving 7 articles that fulfilled the predefined inclusion criteria and were included in the final analysis [20][21][22][23][24][25][26]. A total of 6 publications were full-text articles out the 7 studies [20,[22][23][24][25][26], whereas 1 publication was a meeting conference [21].…”

Modulating the Vascular Response to Limb Ischemia

“…90–94 One study reported significantly fewer patients facing major amputation of a limb in the group infused with PB-MNC versus those in the control group at the conclusion of the studied. 93 …”

Regulating myogenic differentiation of mesenchymal stem cells using thermosensitive hydrogels

“…These include bone marrow and peripheral blood mononuclear cells [11][12][13][14][15][16][17], mesenchymal stem cells (MSCs) [18][19][20][21][22], cell lines selected based on the presence of specific markers [15,[23][24][25], adipose tissue-derived cells [26][27][28][29], and induced pluripotent stem cells-derived cells [30,31]. Each of these cell types has shown promise for the treatment of CLI in mechanistic and preclinical studies.…”